pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,560 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1032Endpoints784BioPharma Dive299BioSpace219Fierce Biotech207onclive165raps78globenewswire health
therapy area
allOncology6093Rare Disease1466Cardiology1094Hematology1031Immunology1014Vaccines918Pulmonology
  • Vera Therapeutics receives accelerated approval for Trutakna to treat IgA nephropathy
    Vera Therapeutics announced that its fusion protein atacicept, branded as Trutakna, has been granted accelerated approval by the FDA for the treatment of immunoglobulin A nephropathy, a chronic aut…
    Endpoints · 1mo agoApprovalPositive↗ source
  • FDA greenlights Vera Therapeutics' Trutakna for IgA nephropathy
    The FDA has approved a new therapy from Vera Therapeutics aimed at treating IgA nephropathy, a chronic autoimmune kidney disorder. The drug, called Trutakna, is intended for patients with this con…
    STAT · 1mo agoApprovalPositive↗ source
← prev
page 48 of 103
next →
73
fda recalls48
fda medwatch41
fda press28
911
Psychiatry & CNS724
Ophthalmology424
Pain406
Endocrinology & Metabolism387
Infectious Disease361
  • Vertex to acquire Crinetics in $10 billion deal, expanding rare endocrine disorder pipeline
    Vertex announced on July 7, 2026 that it will acquire Crinetics Pharmaceuticals for $10 billion, marking the company’s largest-ever transaction. Crinetics is a biotech focused on developing treatm…
    STAT · 1mo agoDealNeutral↗ source
  • Vertex to acquire Crinetics in $10 billion deal, adding rare-disease drug Palsonify to its portfolio
    Vertex Pharmaceuticals announced a $10 billion transaction to purchase Crinetics Pharmaceuticals. The deal will bring Crinetics' recently launched drug Palsonify into Vertex's portfolio. Palsonify…
    STAT · 1mo agoDealPositive↗ source
  • FDA grants accelerated approval to Vera Therapeutics' Trutakna for IgA nephropathy
    The FDA has granted accelerated approval to Trutakna (formerly known as atacicept) from Vera Therapeutics for adult patients with IgA nephropathy, a chronic kidney disease that can progress to rena…
    BioPharma Dive · 1mo agoApprovalPositive↗ source
  • Vertex to buy Crinetics for $10 billion, expanding into endocrine disease drugs
    Vertex announced an agreement to acquire Crinetics Pharmaceuticals for $10 billion in cash, paying $85 per share. The purchase brings two recently launched drugs for a rare hormonal disorder into…
    BioPharma Dive · 1mo agoDealNeutral↗ source
  • CMS launches ACCESS program to reward Medicare digital health solutions that improve outcomes
    The Centers for Medicare & Medicaid Services introduced the ACCESS program, a new initiative that invites digital health companies to participate in Medicare. The program ties Medicare payments to…
    Endpoints · 1mo agoRegulatoryPositive↗ source
  • Oberland invests up to $400M in MeiraGTx eye gene‑therapy pipeline
    Oberland Capital Management announced a financing package that could total $400 million to support MeiraGTx's development of gene therapies for inherited eye disorders. The arrangement includes up…
    BioPharma Dive · 1mo agoDealPositive↗ source
  • Kailera's oral GLP-1 pill shows ~10% weight loss in Chinese Phase 3 trial
    Kailera Therapeutics reported that its oral GLP-1 candidate HRS-7535 achieved about 10% average weight loss over 44 weeks in a Phase 3 study in China. The highest daily dose led to a mean 9.8% red…
    BioPharma Dive · 1mo agoPositive readoutNeutral↗ source
  • STAT newsletter highlights the decline of employer-based health insurance in the U.S.
    John Wilkerson, a Washington correspondent for STAT, writes the D.C. Diagnosis newsletter that focuses on health policy. In this edition he turns his attention to the weakening of the employer-base…
    STAT · 1mo agoNegative↗ source
  • Hengrui and Kailera's oral GLP-1 pill shows promising efficacy but notable side effects in Chinese obesity and diabetes trials
    Hengrui Pharma and Kailera Therapeutics reported results from two late‑stage trials in China, one targeting obesity and the other diabetes, using their daily oral GLP‑1 pill. The studies demonstrat…
    Endpoints · 1mo agoPositive readoutNeutral↗ source
  • STAT+ warns that employer-sponsored health insurance is deteriorating, leaving workers and businesses exposed
    Bob Herman's latest STAT+ newsletter introduces a new series called Out of Pocket, Out of Reach, which will examine how the employer-based health-insurance system is falling apart. The article not…
    STAT · 1mo agoNegative↗ source
  • Novartis, Vertex and Ipsen announce new acquisitions as M&A activity surges in early July 2026
    Biopharma’s merger and acquisition engine remains robust, with four companies revealing new deals within the first six days of July. The announcements add to a total of 45 acquisitions reported in…
    Endpoints · 1mo agoDealPositive↗ source
  • MeiraGTx secures $135 million royalty deal with Oberland Capital
    MeiraGTx announced a royalty financing agreement with Oberland Capital. The deal provides the gene-therapy company with an initial $135 million, including a $10 million equity investment from Oberl…
    Endpoints · 1mo agoDealPositive↗ source
  • Secret shopper study examines GLP-1 prescribing practices on telehealth platforms
    STAT Health Tech newsletter reports a secret shopper study that evaluated how telehealth sites prescribe GLP-1 drugs. The study involved researchers posing as patients to assess prescribing behavi…
    STAT · 1mo agoNeutral↗ source
  • Ebola outbreak highlights gaps in response system
    The recent Ebola outbreak has underscored serious shortcomings in the global and national mechanisms designed to detect and contain emerging infections. Analysts note that the fragmented response…
    STAT · 1mo agoNegative↗ source
  • Small U.S. Businesses Struggle to Provide Health Insurance as Coverage Rates Slip
    America's employer-based health insurance system is becoming unsustainable for small businesses, which form the backbone of many communities. The share of working-age adults receiving coverage thr…
    STAT · 1mo agoNegative↗ source
  • Tampa General Hospital sues Eli Lilly over 340B discount halt
    Tampa General Hospital filed a lawsuit against Eli Lilly, alleging the drugmaker stopped providing 340B program discounts to the hospital. The dispute centers on Lilly's new requirement that hospi…
    Endpoints · 1mo agoRegulatoryNegative↗ source
  • Compass Pathways reports six-month durability of response in pivotal psilocybin depression trial
    Compass Pathways announced that patients in the second of its two pivotal psilocybin trials for depression continued to show a therapeutic response for at least six months. The durability data sugg…
    Endpoints · 1mo agoPositive readoutPositive↗ source
  • Digital health firms eye CMS ACCESS Medicare pilot despite modest reimbursement
    A new Medicare initiative called CMS ACCESS is being launched to manage chronic diseases among seniors. The program will contract digital health companies to provide remote monitoring and other se…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • Georgia entrepreneur struggles to afford health insurance after decades of self‑employment
    Amy Bielawski, a 61‑year‑old owner of an entertainment company in Tucker, Georgia, has spent most of her adult life without health insurance. For 32 years she has run a business that provides bounc…
    STAT · 1mo agoNegative↗ source
  • STAT+: This whistleblower took on a health insurance giant and a political machine. She’s not stopping there
    America’s employers must stop acting helpless in the face of health care industry profiteering, Chris Deacon says.
    STAT · 1mo ago↗ source
  • Opinion: What if this Ebola outbreak can’t be stopped?
    In the past, the possibility of endemic Ebola was unthinkable. This time is different, write Ivan Buendia Gayton and Eric D. Perakslis.
    STAT · 1mo ago↗ source
  • 5 takeaways from STAT’s series on the soaring cost of health insurance
    Read the 5 key takeaways from STAT's series "Out of Pocket, Out of Reach," an examination of workplace health insurance.
    STAT · 1mo ago↗ source
  • French gene therapy biotech gets €33M to follow Krystal's blueprint
    A small French-US biotech has gathered more funds to see if it can follow in the footsteps of Krystal Biotech in the HSV-based gene therapy field, but in a different therapeutic area. Cyllene Thera…
    Endpoints · 1mo ago↗ source